Risk of Psychiatric Adverse Events among Montelukast Users

Project Title Risk of Psychiatric Adverse Events among Montelukast Users
Monday, August 10, 2020

There have been conflicting results from observational studies regarding the risk of psychiatric adverse events (PAEs) with montelukast use. The objective of this study was to determine if there are associations of depressive disorders, self-harm and suicide with use of montelukast compared to inhaled corticosteroid (ICS) use.

Corresponding Author

Efe Eworuke; Division of Epidemiology II, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
Email: efe.eworuke@fda.hhs.gov


Veronica V. Sansing-Foster, Nicole Haug, Andrew Mosholder, Noelle M. Cocoros, Marie Bradley, Yong Ma, Dinci Pennap, Elizabeth C. Dee, Sengwee Toh, Ella Pestine, Andrew B. Petrone, Ivone Kim, Jennifer G. Lyons, Efe Eworuke

Related Assessments
Publication Type
Scroll to Top